Sarepta Therapeutics Retained Earnings (Accumulated Deficit) 2010-2024 | SRPT

Sarepta Therapeutics retained earnings (accumulated deficit) for the quarter ending September 30, 2024 were $-4.370B, a 2.71% decline year-over-year.

  • Sarepta Therapeutics retained earnings (accumulated deficit) for 2023 were $-4.446B, a 13.71% increase from 2022.
  • Sarepta Therapeutics retained earnings (accumulated deficit) for 2022 were $-3.91B, a 21.94% increase from 2021.
  • Sarepta Therapeutics retained earnings (accumulated deficit) for 2021 were $-3.207B, a 12.59% increase from 2020.

Sarepta Therapeutics Retained Earnings (Accumulated Deficit) 2010-2024 | SRPT

  • Sarepta Therapeutics retained earnings (accumulated deficit) for 2023 were $-4.446B, a 13.71% increase from 2022.
  • Sarepta Therapeutics retained earnings (accumulated deficit) for 2022 were $-3.91B, a 21.94% increase from 2021.
  • Sarepta Therapeutics retained earnings (accumulated deficit) for 2021 were $-3.207B, a 12.59% increase from 2020.